Late-Breaking Research: Experimental and Molecular Therapeutics 1

• LB048 ARC-401 - a triple payload first-in-class ADC against Nectin-4 designed to overcome cancer resistance and tumor heterogeneity shows broad anti-tumor activity and high tolerability in rats and non-human primates Isabella Attinger-Toller, Philipp Probst, Romain Bertrand, Rachael Fay, Lia Kallenberger, Ramona Stark, Patrick Maurhofer, Emma Renard, Roger Santimaria, Bernd Schlereth, Dragan Grabulovski, Philipp Rene Spycher
• LB049 · PDF DAC-002, a novel IKZF1/3 MGD-CD38 degrader-antibody conjugate for MM treatment Dihuang Wang, Zheng Xu, Jinhua Wu, Jun Hu, Hanchao Wu, Liwen Zhao
• LB050 · PDF Preclinical development of a potential first-in-class CDH17/CEACAM5 targeted bispecific antibody drug conjugate (ADC) Jun Xu, Qingyuan Meng, He Li, Dong Yao, Tao Peng, Haoliang Zhang, Yao Li, Mingjing Yan, Ruofeng Tang, Jie Yang, Dan Wei, Pingming Tang, Ju Wang, Pangke Yan
• LB051 BCG048, a novel bispecific dual-payload ADC targeting ITGB6 and B7H3, exhibited potent efficacy in patient-derived tumor xenograft models Benny Yang, Mengran Li, Haipeng Liu, Chengzhang Shang
• LB052 Unlocking the Full Human Antibody Repertoire: Novel Humanized Antibody Mouse Models with Fully Humanized Lambda Chains and Diversified Genetic Backgrounds Benny Yang, Lili Liu, Lijun Zhang, Yanshuang Li, Huizhen Zhao, Jiawei Yao
• LB053 A novel CD16A-nanobody platform overcomes Fc polymorphism limitations for potent and broad-spectrum NK cell engager therapeutics Tiong Sun Chia, Jia Liu, Shuming Lin, Wei Dai, Min Wu, Zhihai Wu
• LB054 Preclinical characterization of HSC00189, a novel bispecific ADC targeting cadherin-6 (CDH6) and folate receptor alpha (FOLR1) for the treatment of ovarian cancer Hongbin Wang, Qingyuan Meng, He Li, Dong Yao, Tao Peng, Lei Chen, Yao Li, Zhijian Yao, Dengfeng Duan, Ruofeng Tang, Senlin Li, Hongjiao Dong, Pingming Tang, Min Xu, Yao Lu, Ju Wang, Pangke Yan
• LB055 · PDF Novel hydrophilic linker to improve stability and in vitro activity of antibody-drug conjugates Kern H. Chang, Byoung Chul Lee
• LB056 · PDF Inhibiting WEE1 kinase enhances sensitivity of high grade serous ovarian cancer cells to the novel KIF18A inhibitor ATX020 Jayakumar R. Nair, Tzu-Ting Huang, Maureen Lynes, Serena Silver, Laura Ghisolfi, Stanley Lipkowitz, Jung-Min Lee
• LB057 Repurposing statins for locally advanced esophageal adenocarcinoma: Integrating scRNAseq, organoid based high throughput drug screening, and patient level clinical data Sanjima Pal, Luís Nuno Cruz Santos Castro, Megan Sperry, Qian Qiu, Shuyuan Wang, Mingyan (Iris) Kong, Nicholas Bertos, Betty Giannias, Cedric Julien, Wotan Zeng, Swneke Bailey, Donald E. Ingber, Lorenzo Ferri
• LB058 Clinically actionable drug synergy drives transcriptomic and metabolic reprogramming to induce ferroptosis and apoptosis in triple negative breast cancer Gokul M. Das, Chetan C. Oturkar, Junhyoung Park, Iqbal Aijaz, Christina Adams, Utpakl K. Mukhopadhyay, Melissa Dolan, Michalis Mastri, Alexan der J. Caradori, Manasori Oshi, Yali Zhang, Jianmin Zhang, Brent Boleslav, Donald Mager, Tagari Samanta, Seung Y. Yabn, Richa Mishra, Richa Mishra, John Ebos, Kazuaki Takabe, Kris Attwood, Beeny A. Kaipparettu
• LB059 · PDF Pan-GATA molecular glues as novel tools for targeted degradation of GATA3in ER+breast cancers Clementine Feau, Kalyani Gampa, Evan T. Judd, Raundi Quevedo, Hedy Chan, Carmine Fedele, Jess Griffith, Michael Visser, Nertila Siuti, Fei Ji, Zainab Jagani
• LB060 · PDF Systematic discovery and validation of tumor-specific splice isoforms in endometrial cancer Evgeny Kiner, Alina Kline-Schoder, Antonino Montalbano, Bar Rozenman, Erin Jeffery, Vasilii Pavelko, Katia Sol-Church, Nidhi Sahni, David A. Knowles, Gloria Sheynkman
• LB062 DEM301, a novel bifunctional ADC with potent immunomodulatory activity for potential use in difficult to treat colorectal malignancies Agnieszka Denslow, Sarah E. Carden, Peter Sandy, Sandeep Kumar, Loise M. Francisco
• LB063 · PDF A novel oral G-quadruplex stabilizer for the treatment of DNA repair-deficient cancers, including brain metastases Shuang Liu, Lei Zhang, Fanxin Zeng, Hong Xu
• LB064 · PDF Disruption of melanoma cell proliferation by inhibition of KIFC1 Davis Mau, Mary A. Ndiaye, Nihal Ahmad
• LB066 · PDF Orthosteric and allosteric determinants of CRAF binding to RAS Oliver Priebe, Chandni Khandwala, Francisco Guedes, Max Seaman, Sabine Ruppel, Adam Yaari, Maxwell Sherman
• LB067 A modular Multi-Antigen T Cell Hybridizers (MATCH) platform enables tunable and potent immunotherapy across hematologic and solid tumors Shannuo Li, Yingduo Yang, Joseph Shami, Douglas Sborov, Paul Shami, Jiyuan Yang, Jindřich Kopeček
• LB068 · PDF Oral fulvestrant nanoparticles deliver high, sustained exposure: An alternative to IM injection Richard A. Graves, Hossain Ahamed, Changde Zhang, Guangdi Wang, Tarun K. Mandal
• LB069 · PDF PLB-015 a novel anti-HER2 dual payload ADC for the treatment of HER2 positive solid tumors Yingdong Lu, Guangchao Zhang, Junqi Zhu, Ya Zhang, Haobo Tang, Haitao Pan, Zhengli Xu, Huixia Zhang, Shasha Li, Kia Joo Puan, Ling Xu, Xinhao Zhao, Zhengquan Zhang, Wei Lu, Yarong Qu, Mao Yin
• LB070 · PDF Discovery of Helicon peptides that selectively degrade the agonist-bound androgen receptor (AR ON ) in prostate cancer Diwakar R. Pattabiraman, Brandon Nicolay, Pieter Beerepoot, Kelsey Barrasso, Dorothy Brach, Sascha DeVine, Lee Belding, Paula Ortet, Anthony Quartararo, Archana Iyer, Yelena Arnautova, David Terry, Dakota Hawkins, Shelagh Fluharty, Amelia K. Luciano, Brandon Hriniak, Mousa Jafari, Anandan Palani, Donovan Chin, Markus Haeberlein, Jonathan Hurov
• LB071 · PDF Combination of isorhapontigenin and FSP1 inhibitor suppresses triple negative breast cancer cell progression Franklin Tran, Yvette Shteynfeld, Sydney Tsao, Hong Sun, Wei Dai

在完整检索应用中浏览本分会场 →